{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:23Z","timestamp":1787023283684,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in the diagnostic algorithm of entero-pancreatic neuroendocrine neoplasms (EP NENs) is unclear because most available data derive from heterogeneous populations in terms of tumor biology and disease status at time of examination. The aim of this study was to determine the ability of 18F-FDG PET to identify patients with more aggressive disease among those with advanced EP NENs.<\/jats:p>\n                    <jats:p>Subjects, Materials, and Methods . Patients with advanced EP NENs and known disease status (progressive disease [PD] or stable disease [SD]) according to imaging procedures, who received 18F-FDG PET and computed tomography scans during a time frame of 1 month, were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 93 patients, including 69 patients with pancreatic NENs and 24 patients with small-intestine NENs, were included. At the time of study entry, 64 patients (68.8%) had PD, and the remaining 29 patients (31.2%) had SD. A total of 62 patients (66.7%) had positive 18F-FDG PET, whereas 18F-FDG PET was negative in the remaining 31 patients (33.3%). Overall, 18F-FDG PET sensitivity and specificity to detect PD were 90.6% and 86.2%, respectively, resulting in a diagnostic accuracy of 89.2%. A positive 18F-FDG PET was significantly associated with PD at the time of study entry (p\u2009&amp;lt;\u2009.0001 at multivariate analysis). Although a higher proportion of 18F-FDG PET-positive examinations were observed in patients with higher tumor grade (p\u2009=\u2009.01), 53.8% of patients with grade 1 neuroendocrine tumors (NETs) had positive 18F-FDG PET, and 37.5% of patients with grade 2 NETs had negative 18F-FDG PET. Overall survival was significantly shorter in 18F-FDG PET-positive patients (median: 60 months) in comparison with 18F-FDG PET-negative patients (median not reached; p\u2009=\u2009.008).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>18F-FDG PET has a high diagnostic accuracy to identify progression of disease with unfavorable clinical outcome in patients with advanced EP NENs. Knowledge of disease status and G grading are key factors for physicians to better select patients for whom 18F-FDG PET is clinically useful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>The findings of the present study may help physicians dealing with advanced neuroendocrine neoplasms to select patients for whom 18F-fluorodeoxyglucose positron emission tomography is useful to predict poor clinical outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0278","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T16:50:15Z","timestamp":1510159815000},"page":"186-192","source":"Crossref","is-referenced-by-count":43,"title":["Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms"],"prefix":"10.1093","volume":"23","author":[{"given":"Maria","family":"Rinzivillo","sequence":"first","affiliation":[{"name":"Digestive and Liver Disease Unit, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Partelli","sequence":"additional","affiliation":[{"name":"Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita e Salute University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Prosperi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Capurso","sequence":"additional","affiliation":[{"name":"Digestive and Liver Disease Unit, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pizzichini","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Iannicelli","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elettra","family":"Merola","sequence":"additional","affiliation":[{"name":"Digestive and Liver Disease Unit, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Muffatti","sequence":"additional","affiliation":[{"name":"Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita e Salute University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scopinaro","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Salgarello","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ospedale Sacro Cuore Don Calabria, Negrar, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[{"name":"Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita e Salute University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Delle Fave","sequence":"additional","affiliation":[{"name":"Digestive and Liver Disease Unit, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[{"name":"Digestive and Liver Disease Unit, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"2021122509423390700_onco12306-bib-0001","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122509423390700_onco12306-bib-0002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000457956","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Pathology, diagnosis and prognostic stratification","volume":"105","author":"Perren","year":"2017","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0003","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1634\/theoncologist.2016-0351","article-title":"Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: A risk score to predict clinical outcome","volume":"22","author":"Panzuto","year":"2017","journal-title":"The Oncologist"},{"key":"2021122509423390700_onco12306-bib-0004","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djs208","article-title":"TNM staging of neoplasms of the endocrine pancreas: Results from a large international cohort study","volume":"104","author":"Rindi","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2021122509423390700_onco12306-bib-0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cncr.23549","article-title":"Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors","volume":"113","author":"Pape","year":"2008","journal-title":"Cancer"},{"key":"2021122509423390700_onco12306-bib-0006","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","article-title":"Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization","volume":"12","author":"Panzuto","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"2021122509423390700_onco12306-bib-0007","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2010.33.0688","article-title":"Metastatic and locally advanced pancreatic endocrine carcinomas: Analysis of factors associated with disease progression","volume":"29","author":"Panzuto","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122509423390700_onco12306-bib-0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000334038","article-title":"Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors","volume":"96","author":"Panzuto","year":"2012","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0009","first-page":"3837","article-title":"Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography","volume":"6","author":"Vesselle","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021122509423390700_onco12306-bib-0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJM200007273430404","article-title":"Preoperative staging of non-small-cell lung cancer with positron-emission tomography","volume":"343","author":"Pieterman","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122509423390700_onco12306-bib-0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"2021122509423390700_onco12306-bib-0012","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122509423390700_onco12306-bib-0013","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/annonc\/mdi127","article-title":"Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20\u201321 March 2004, under the auspices of ESMO","volume":"16","author":"Blay","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122509423390700_onco12306-bib-0014","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/cncr.21569","article-title":"The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases","volume":"104","author":"Wiering","year":"2005","journal-title":"Cancer"},{"key":"2021122509423390700_onco12306-bib-0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s002689900439","article-title":"Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?","volume":"22","author":"Pasquali","year":"1998","journal-title":"World J Surg"},{"key":"2021122509423390700_onco12306-bib-0016","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"key":"2021122509423390700_onco12306-bib-0017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000368609","article-title":"The role of combined Ga-DOTANOC and (18)FDG PET\/CT in the management of patients with pancreatic neuroendocrine tumors","volume":"100","author":"Partelli","year":"2014","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0018","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"6","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122509423390700_onco12306-bib-0019","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2967\/jnumed.108.057505","article-title":"Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors","volume":"50","author":"Garin","year":"2009","journal-title":"J Nucl Med"},{"key":"2021122509423390700_onco12306-bib-0020","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","article-title":"High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: A long-term evaluation","volume":"55","author":"Bahri","year":"2014","journal-title":"J Nucl Med"},{"key":"2021122509423390700_onco12306-bib-0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MPA.0000000000000745","article-title":"Role of combined 68Ga-DOTATOC and 18F-FDG positron emission tomography\/computed tomography in the diagnostic workup of pancreas neuroendocrine tumors: Implications for managing surgical decisions","volume":"46","author":"Cingarlini","year":"2017","journal-title":"Pancreas"},{"key":"2021122509423390700_onco12306-bib-0022","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment","volume":"92","author":"Therasse","year":"2000","journal-title":"of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst"},{"key":"2021122509423390700_onco12306-bib-0023","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122509423390700_onco12306-bib-0024","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/S1590-8658(11)60591-4","article-title":"Gastroenteropancreatic (neuro)endocrine neoplasms: The histology report","volume":"43(suppl4","author":"Rindi","year":"2011","journal-title":"Dig Liver Dis"},{"key":"2021122509423390700_onco12306-bib-0025","author":"Bosman","year":"2010"},{"key":"2021122509423390700_onco12306-bib-0026","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"2021122509423390700_onco12306-bib-0027","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"2021122509423390700_onco12306-bib-0028","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000225945","article-title":"ENETS consensus guidelines for the standard of care in neuroendocrine tumors","volume":"90","author":"Pl\u00f6ckinger","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0029","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000225946","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with (111)in-pentetreotide","volume":"90","author":"Kwekkeboom","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0030","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2967\/jnumed.114.137166","article-title":"Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: Feasibility of a metabolic grading system","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"},{"key":"2021122509423390700_onco12306-bib-0031","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1210\/jc.2016-3732","article-title":"Functional imaging in the follow-up of enteropancreatic neuroendocrine tumors: Clinical usefulness and indications","volume":"102","author":"Merola","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122509423390700_onco12306-bib-0032","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0033","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic Neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0034","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/jhbp.226","article-title":"Clinical features of pancreatic neuroendocrine tumors","volume":"22","author":"Grozinsky-Glasberg","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2021122509423390700_onco12306-bib-0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/jso.24116","article-title":"Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms","volume":"113","author":"Kaltenborn","year":"2016","journal-title":"J Surg Oncol"},{"key":"2021122509423390700_onco12306-bib-0036","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (nen) and nen of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2021122509423390700_onco12306-bib-0037","author":"National Comprehensive Cancer Network"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/2\/186\/41915995\/oncolo_23_2_186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/2\/186\/41915995\/oncolo_23_2_186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T04:44:08Z","timestamp":1640407448000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/2\/186\/6439242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,11,8]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0278","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2,1]]},"published":{"date-parts":[[2017,11,8]]}}}